Kedrion received QSEAL certification from PPTA
Kedrion has been awarded Quality Standards of Excellence, Assurance, and Leadership (QSEAL) certification from the Plasma Protein Therapeutics Association (PPTA). The international QSEAL Program relies on independent, third-party evaluation and recognizes strict adherence to a set of voluntary standards, which underscore the industry’s quality and safety commitment to patients who rely on essential plasma protein
Growth of the Kedrion Group: expansion of the Hungarian plant starting now. A new Plasmaphereris centre settled in Budapest
Kedrion Group’s growth strategy is progressing in two directions: one is the vertical integration of its operations, the other is the expansion of its production capacity aimed at consolidating its international market share, especially in Europe. The start of the upgrading and expansion of the Gödöllo plant, commissioned to the Engineering Company Foster Wheeler Italiana
Haemophilia: Kedrion wins award in India
Kedrion has won the institutional Haemophilia Federation India (HFI) award. As part of the celebrations for the 25th anniversary of the foundation of HFI, in New Delhi, India’s Health and Welfare Minister Ambumani Ramadoss gave Kedrion’s Piersergio Martini an award for the company’s long-term support to the mission of increasing the availability of coagulation factors, i.e.
Kedrion: AIFA’s incentives to seven investment plans
AIFA, the Italian Medicine Agency, will give the incentives planned under the 2008 framework agreements to seven investment plans submitted by Kedrion, a biopharmaceutical company which is the national leader in the development, manufacture and distribution of plasma derivative medicines. This accolade by AIFA – which has allocated 3,184,025 euros’ worth of resources to investments
Kedrion Group: investments and acquisitions to expand its market share
Kedrion Group, the Italian leader in the development, manufacture and distribution of plasma derived medicinal products, continues its investment policy. Composed of nine companies based in the United States, Mexico, Switzerland, Germany, Austria and Hungary, the eighth largest group in the world, with offices in over 40 countries, Kedrion group has started a new reorganisation
Increased product range: studies on Fibrin Glue just started
Kedrion’s initiatives to strengthen and extend its market share are going on. With the start of its clinical trials on fibrin glue, the company started a plan that, if these trials prove successful, should enable it to market the new product in 2011. In order to extend its product range, the company started clinical trials
New method for the purification of Factor VIII VIII/FVW concentrate study published on
The study Progress in large-scale purification of Factor VIII/von Willebrand factor concentrates using ion-exchange chromatographyhas been published on “Vox Sanguinis” (2008) 95, 298–307, Entirely conducted by Kedrion’s researchers, the study presents the results of the development of a new purification method for a Factor VIII/von Willebrand Factor concentrate. A process scale-up is now being investigated
Viral Risk Assessment: Kedrion wins the SIMTI award
As part of the XXXVIII National Conference on Transfusion Medicine, the Scientific Committee of SIMTI (Italian Society of Transfusion and Immunohaematologic Medicine) has selected, as the winner for the session “transfusion-transmitted diseases”, the presentation Viral Risk Assessment – Modello Kedrion: applicazione nell’ambito del plasma italiano destinato alla lavorazione industriale (Viral Risk Assessment – Kedrion’s model:
Four new departments in the Bolognana site. Investiments in continuous plant and process improvement Keep Flowing
The investments for the continuous improvement of the manufacturing processes and plants of Kedrion are going on at a fast pace. After passing the AIFA inspection (AIFA is the Italian Drugs Agency) and proving to comply with international Good Manufacturing Practices (GMP), the process for the authorisation to operate with four new departments in the
Agreement between Kedrion and ProMetic for the development of Hyperimmune products
Kedrion S.p.A. and ProMetic Life Sciences Inc. (TSX:PLI) announced that they have signed the definitive agreement for two hyperimmunes. The first product to be developed will target the Hepatitis B Hyperimmune. Kedrion has in-licensed ProMetic’s technologies for the manufacturing of hyperimmune products in Europe. Royalties, licensing and service fees for the sales of products in
